Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,542,888
  • Shares Outstanding, K 1,254,313
  • Annual Sales, $ 27,305 M
  • Annual Income, $ 6,225 M
  • 60-Month Beta 0.38
  • Price/Sales 2.96
  • Price/Cash Flow 7.18
  • Price/Book 4.05
Trade GILD with:

Options Overview Details

View History
  • Implied Volatility 25.37% ( +0.89%)
  • Historical Volatility 22.40%
  • IV Percentile 66%
  • IV Rank 38.62%
  • IV High 39.76% on 03/01/22
  • IV Low 16.32% on 09/08/21
  • Put/Call Vol Ratio 0.82
  • Today's Volume 20,454
  • Volume Avg (30-Day) 12,379
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 449,422
  • Open Int (30-Day) 477,890

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 1.52
  • Number of Estimates 10
  • High Estimate 1.73
  • Low Estimate 1.29
  • Prior Year 1.87
  • Growth Rate Est. (year over year) -18.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.15 +8.99%
on 05/02/22
65.46 -1.51%
on 05/26/22
+2.70 (+4.37%)
since 04/26/22
3-Month
57.19 +12.74%
on 03/16/22
65.46 -1.51%
on 05/26/22
+3.35 (+5.48%)
since 02/25/22
52-Week
57.19 +12.74%
on 03/16/22
74.12 -13.02%
on 12/30/21
-1.88 (-2.83%)
since 05/26/21

Most Recent Stories

More News
3 Low-Beta Stocks to Buy to Combat a Jittery Market

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties,...

ABC : 155.80 (+0.99%)
GILD : 64.47 (-0.83%)
MRK : 92.31 (-1.54%)
The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical

JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.

JPM : 129.44 (+1.73%)
CSX : 31.58 (+1.38%)
GILD : 64.47 (-0.83%)
SNP : 52.86 (+1.85%)
CVS : 97.80 (+0.67%)
Top Research Reports for JPMorgan, Gilead Sciences & CSX

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).

JPM : 129.44 (+1.73%)
CSX : 31.58 (+1.38%)
GILD : 64.47 (-0.83%)
SNP : 52.86 (+1.85%)
CVS : 97.80 (+0.67%)
PGR : 116.81 (+1.03%)
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA)....

GILD : 64.47 (-0.83%)
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates

Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.

BMY : 77.59 (+0.45%)
GILD : 64.47 (-0.83%)
CMRX : 1.7700 (-1.12%)
BBIO : 6.62 (-0.15%)
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022...

GILD : 64.47 (-0.83%)
30+ Stocks To Own Based On Top Wall Street Hedge Fund 13F Filings

13F filings can reveal a lot about a fund's holdings. Here is what some of the Top Hedge Funds own based on recently filed 13F data.

VWO : 42.58 (+1.50%)
PG : 146.48 (+0.87%)
IEMG : 51.29 (+1.46%)
EEM : 41.57 (+1.56%)
SPY : 405.31 (+2.00%)
BABA : 94.48 (+14.79%)
JNJ : 179.46 (-0.09%)
KO : 64.30 (+0.36%)
PEP : 170.11 (+0.67%)
COST : 464.99 (+5.65%)
NVO : 106.60 (+1.28%)
TSLA : 707.73 (+7.43%)
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold

Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.

GSK : 44.42 (-1.22%)
GERN : 1.2900 (unch)
ALKS : 29.36 (+1.77%)
GILD : 64.47 (-0.83%)
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate...

GILD : 64.47 (-0.83%)
3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure,...

GILD : 64.47 (-0.83%)
GSK : 44.42 (-1.22%)
TAK : 14.84 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 66.13
2nd Resistance Point 65.80
1st Resistance Point 65.13
Last Price 64.47
1st Support Level 64.13
2nd Support Level 63.80
3rd Support Level 63.13

See More

52-Week High 74.12
Fibonacci 61.8% 67.65
Fibonacci 50% 65.65
Last Price 64.47
Fibonacci 38.2% 63.65
52-Week Low 57.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar